Research Paper Volume 15, Issue 12 pp 5673—5697

DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma

Feng Xiao1,2,3,4, , Hong Zhu1,2,3,4, , Yun Guo1,2,3,4, , Zhe Zhang1,2,3,4, , Gufeng Sun1,2,3,4, , Kai Huang1,2,3,4, , Hua Guo1,2,3,4, , Guowen Hu1, ,

  • 1 Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
  • 2 Jiangxi Key Laboratory of Neurological Tumors and Cerebrovascular Diseases, Nanchang 330006, Jiangxi, China
  • 3 Jiangxi Health Commission Key Laboratory of Neurological Medicine, Nanchang 330006, Jiangxi, China
  • 4 Institute of Neuroscience, Nanchang University, Nanchang 330006, Jiangxi, China

Received: February 7, 2023       Accepted: June 6, 2023       Published: June 29, 2023
How to Cite

Copyright: © 2023 Xiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: The role of dual-specificity phosphatase 10 (DUSP10) has been investigated in several types of cancer. Nevertheless, the underlying function of DUSP10 in lower-grade glioma (LGG) remains undetermined.

Methods: We entirely determined the expression features and prognostic significance of DUSP10 in numerous tumors by implementing a pan-cancer analysis. Adjacently, we thoroughly inspected the correlation between DUSP10 expression and clinicopathologic features, prognosis, biological processes, immune traits, gene variations, and treatment responses based on the expression features in LGG. In vitro studies were conducted to detect the underlying functions of DUSP10 in LGG.

Results: Unconventionally boosted DUSP10 expression and higher DUSP10 expression correlated with poorer prognosis were discovered in various tumors, including LGG. Fortunately, DUSP10 expression was proven to be an independent prognostic indicator of patients with LGG. Additionally, DUSP10 expression was tightly linked to the immune modulation, gene mutations, and response to immunotherapy/chemotherapy in LGG patients. In vitro studies illustrated that the DUSP10 was abnormally increased and pivotal for cell proliferation in LGG.

Conclusions: Collectively, we verified that DUSP10 was an independent prognostic indicator and may become a novelty target of targeted therapy of LGG.


DUSP10: dual-specificity phosphatase 10; LGG: lower-grade glioma; ICPGs: immune checkpoint genes; CNA: copy number alteration; TMB: tumor mutation burden; WHO: World Health Organization; TCGA: The Cancer Genome Atlas; CGGA: Chinese Glioma Genome Atlas; GEO: Gene Expression Omnibus; IDH: isocitrate dehydrogenase; ssGSEA: single-sample GSEA; GTEx: Genotype-Tissue Expression; OS: overall survival; KM: Kaplan-Meier; ICB: immune checkpoint blockers; ROC: receiver operating characteristics; AUC: area under the curve; FDR: false-discovery rate; DEGs: differentially expressed genes; GO-BP: Gene Ontology biological process; KEGG: Kyoto Encyclopedia of Genes and Genomes; IC50: lower inhibitory centration.